SCHEMBL1009040

SCHEMBL1009040

COC(=O)C(CC1CCCC1)n1ncc(Oc2nc(C)cc(C)n2)c(Cl)c1=O

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCK P35557 8/20 0.35
P2RX3 P56373 4/20 0.34
KAT2B Q92831 1/20 0.33
EDNRB P24530 2/20 0.33
EDNRA P25101 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
NPBWR1 P48145 1/20 0.32
GAA P10253 1/20 0.32
MITF O75030 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
RECQL P46063 1/20 0.32
RAB9A P51151 1/20 0.32
MDM2 Q00987 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010562 0.82 ALDH1A1 (0.47) GCKP2RX3KAT2BSMN1; SMN2NPBWR1
SCHEMBL1008294 0.82 GCK (0.36) GCKP2RX3EDNRBEDNRASMN1; SMN2
SCHEMBL1008225 0.81 LMNA (0.36) GCKP2RX3KAT2BSMN1; SMN2NPBWR1
SCHEMBL1008644 0.75 NPY5R (0.39) SMN1; SMN2NPBWR1MITFALDH1A1LMNA
SCHEMBL1008502 0.74 PREP (0.41) GCK
SCHEMBL1065040 0.73 L3MBTL1 (0.40) GCKALDH1A1MAPTNPSR1
SCHEMBL1007685 0.72 EDNRB (0.39) GCKEDNRBEDNRASMN1; SMN2GAA
SCHEMBL1009410 0.72 GCK (0.37) GCK
SCHEMBL1007711 0.71 GCK (0.36) GCKOPRK1
SCHEMBL1008591 0.71 GCK (0.37) GCKNPBWR1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK GCK 1/4885P2RX3 2029/4885KAT2B 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.